Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 16Phase 3 13Phase 1/2 5Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Sezary Syndrome 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Large Granular Lymphocytic 1Burkitt Lymphoma 1

Interventions

blinatumomab 4Dexamethasone 3Vincristine 2Methotrexate 2Cyclophosphamide 2venetoclax 1tocilizumab 1siltuximab 1fludarabine phosphate 1epratuzumab 1Whole-Body Irradiation 1Thiotepa 1Radioimmunodetection 1Prednisone 1Melphalan 1Etoposide 1Diphenhydramine 1Daunorubicin 1Cytarabine 1Carboplatin 1Busulfan 1Asparaginase 1Antilymphocyte Serum 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Burkitt Lymphoma × Prednisone × Clear all
NCT06882057 2025-08-26

CCCG-LR-B-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
3,000 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡